tbuckley/cabot-search huggingface dataset:
Kidney Homotransplantation in the Human
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Ciprofloxacin Otic Suspension (Otiprio) for Acute Otitis Externa
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correlation between HBV core-related antigen and the new quantitative IGG anti-core in treated caucasian HBeAg-negative patients and inactive carriers with and without a functional cure
Authors: Alessandro Loglio, Floriana Facchetti, Elisa Farina, Nicoletta Nandi, Alberto Perego, Riccardo Perbellini, Sara Colonia Uceda Renteria, Marta Borghi, Roberta Soffredini, Corinna Orsini, Giovanna Lunghi, Ferruccio Ceriotti, Pietro Lampertico
Journal: Journal of Hepatology (2020)
Transplantation antibodies in human recipients of renal homografts
Authors: G. M. Williams
Journal: JAMA (1968)

Transplantation antibodies in the sera of eight patients who survived rejection of one or two renal grafts were studied by the mixed agglutination tests with cell cultures. Evidence that transplantation antibodies are removed from the recipient's circulation by the functioning graft was as follows: (1) the antibodies were detected in sera of the patients during the terminal stage of rejection or after the removal of the graft but never during the normal function of the graft; (2) the antibodies could be eluted from the rejected grafts. Present data also brought some evidence for the possible participation of humoral antibodies in rejection of renal grafts.
In This Issue
Journal: Circulation Research (2012)

Inhibition of miR-155 Reduces Myocardial Damage (p 415)Blocking the activity of a microRNA called miR-155 could improve the outcome of viral myocarditis, report Corsten et al.Certain viruses, such as coxsackievirus, make a beeline for the heart, where they infect cells, replicate, and generally wreak havoc.The resulting viral myocarditis could cause irreversible cardiomyocyte damage and interstitial fibrosis, which can lead to heart failure and sudden cardiac death.Corsten et al have now discovered that miR-155 worsens this viral damage.The authors analyzed differentially expressed miRs in coxsackievirussusceptible versus coxsackievirus-resistant mice.They found a large number of such miRs, of which only 16 were also found to be changed in human patients with viral myocarditis.The authors focused on one of the 16 miRs, namely miR-155, because it is known to be involved in inflammation.The authors discovered that in inflamed mouse and human hearts, miR-155 expression was significantly ramped up in infiltrating inflammatory cells, particularly in T cells and macrophages.Blocking miR-155 activity in mice with a targeted synthetic nucleic acid reduced both cardiac inflammation and injury and improved cardiac function and mouse survival.miR-155 might therefore be a potential therapeutic target to improve the prognosis of patients with viral myocarditis, say the team.
Manuscripts Approved for JNCI, February 10 to March 10, 1964
Journal: JNCI Journal of the National Cancer Institute (1964)

Journal Article Manuscripts Approved for JNCI, February 10 to March 10, 1964 Get access JNCI: Journal of the National Cancer Institute, Volume 32, Issue 4, April 1964, Pages 960–961, https://doi.org/10.1093/jnci/32.4.960-a Published: 01 April 1964
Job loss due to health insurance mandates
Authors: J. A. Klerman
Journal: JAMA (1994)

The proposed Health Security Act provides universal health insurance by extending the current employer-based health insurance financing system. It requires employers to pay approximately 80% of the health insurance premium for each of their workers. Experience with other legislation requiring employers to provide benefits to their employees indicates that most of the cost of a mandated benefit is shifted to employees in the form of lower wages. However, for workers without health insurance and with earnings close to the minimum wage, minimum-wage legislation prohibits employers from lowering wages in response to a health insurance mandate. These employers can be expected to respond by cutting employment. Recent evidence from employer reactions to increases in the minimum wage suggests that approximately 100 000 jobs would be lost due to the Health Security Act's employer mandate. (<i>JAMA</i>. 1994;272:552-556)
TR-13 * EFFECTS OF EVEROLIMUS ON MENINGIOMA GROWTH IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 2
Authors: D. Osorio, A. Filatov, M. Hagiwara, C. Mitchell, J. Wisoff, J. Golfinos, J. T. Roland, J. Allen, M. Karajannis
Journal: Neuro-Oncology (2015)
Cephalosporin-associated pseudomembranous colitis due to Clostridium difficile
Authors: J. G. Bartlett
Journal: JAMA (1979)

Recent studies have shown considerable progress in the diagnosis, etiology, and therapy of antibiotic-associated pseudomembranous colitis. Previous work has implicated a number of antimicrobial agents, but there are relatively few reports concerning the role of cephalosporins. The subject of the present report is 17 patients with pseudomembranous colitis associated with cephalosporin use. Tissue cultures of stools from all patients showed a cytotoxin that is neutralized by C<i>sordellii</i>antitoxin. Bacterial cultures of these specimens yielded strains of C<i>difficile</i>that produced a similar cytotoxin in vitro. Nine of the patients were treated orally with vancomycin hydrochloride and all responded. This experience illustrates the importance of considering the diagnosis of pseudomembranous colitis in patients in whom diarrhea develops in association with cephalosporin use. (<i>JAMA</i>242:2683-2685, 1979)
Hospital Career Structure
Authors: D. C. Banks, M. Baum, C. Brown, J. A. Chalmers, J. L. Day, R. P. Foster, D. I. R. Higton, C. Hodgson, B. M. Hogbin, E. R. Jones, V. V. Kakkar, C. -C. Lim, I. J. Lord, R. Loveday, J. D. Parkes, I. D. Ramsay, B. J. Sykes, A. R. Tanser
Journal: BMJ (1968)
ANNUAL MEETING OF FELLOWS AND MEMBERS OF THE ROYAL COLLEGE OF SURGEONS OF ENGLAND
Journal: BMJ (1909)

99statement such comparisons are impossible.Four groups of facts may be conveniently symbolised to record progress: systemic disturbance, respiratory disturbance, complications present, and capacity for exercise or work.The first three may be recorded in one of three degrees, the last in hours per day.All these should be subordinate to the anatomical condi- tion, which is more permanent and better suited as a basis for classification.
<i>QuickStats</i>: Percentage Distribution of Gestational Age in Weeks for Infants Who Survived to Age 1 Year and Infants Who Died Before Age 1 Year — National Vital Statistics System, United States, 2014
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

Infants who do not survive the first year of life are more likely to be born at earlier gestational ages. In 2014, 66% of infants who survived to age 1 year were delivered at full term or later (≥39 completed weeks) compared with 16% of infants who died before reaching age 1 year. Fifty-eight percent of infants who died before age 1 year were delivered at <32 weeks gestation compared with only 1% of infants who survived to age 1 year.
Harrisburg Hospital Omitted
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
American Obstetrics
Authors: M. P. Embrey
Journal: BMJ (1963)

<h3>Introduction</h3> Aneurysms at the origin of the posterior communicating artery (PcommA) have been demonstrated to be effectively treated with the Pipeline Embolization Device (PED). Much less is known about the efficacy of the PED for aneurysms associated with a fetal posterior cerebral artery (fPCA) variant. Herein, the largest series of patients with ICA aneurysms at the origin of the PcommA or fPCA treated with the PED is presented. <h3>Methods</h3> A prospectively maintained university database of aneurysm patients treated with the PED was retrospectively reviewed. Demographics, treatment details, and imaging were reviewed for all PcommA and fPCA aneurysms. <h3>Results</h3> Out of a total of 285 patients treated with PED, 50 patients (mean age 57.5±12.2 years, 42 females) with unruptured PcommA (9 fPCA) aneurysms were identified. Mean follow-up duration was 14.0±11.6 months (48 patients). Roy-Raymond Class I occlusion on follow up Magnetic Resonance or catheter angiography (mean time 11.7±6.8 months) was achieved in 30 patients (62.5%), Class II occlusion in 11 patients (22.9%) and Class III occlusion in 7 patients (14.5%). The PcommA was occluded in 56% of patients without any clinical symptoms. No deaths or permanent neurological complications occurred. In fPCA aneurysms, Class I occlusion was seen in 1 patient, Class II occlusion in 2 patients, and Class III occlusion in 6 patients (figure 1). Multivariate analysis revealed an independent association between incomplete occlusion and fPCA configuration (OR 73.65; 95% CI [5.84–929.13]; p=0.001). The current literature on flow diversion treatment of fPCA aneurysms was reviewed and added to the current series and found to be associated with a low rate of aneurysm occlusion (5/23 or 22%; table 1). <h3>Conclusion</h3> PEDs are a safe and effective choice in the treatment of PcommA aneurysms. The presence of fetal anatomy, however, should increase consideration of traditional intra-saccular endovascular techniques or surgical clipping. Longer follow-up is needed to determine the ultimate efficacy of PED treatment for these aneurysms. <h3>Disclosures</h3> <b>A. Roy:</b> None. <b>B. Howard:</b> None. <b>D. Haussen:</b> None. <b>J. Osbun:</b> None. <b>S. Halani:</b> None. <b>S. Skukalek:</b> None. <b>F. Tong:</b> None. <b>R. Nogueira:</b> None. <b>J. Dion:</b> None. <b>C. Cawley:</b> None. <b>J. Grossberg:</b> None.
Maternal exposure to potential teratogens
Authors: J. J. Nora
Journal: JAMA (1968)

<h3>To the Editor:—</h3> As an obstetrician, I have read with interest the paper of Nora et al, "Maternal Exposure to Potential Teratogens" (<b>202</b>: 1065, 1967). I believe the paper poses several questions, the first being the criteria used by the authors for the selection of "potential" teratogens. Since the apparent criteria were "hazards known to be or suspected of being teratogenic to man or other species," I wonder why their list did not include such "potential" teratogens as cosmic rays, high altitudes, emotional upsets, inadequate diets, amplified sounds, etc? Indeed, a list of agents which are not "potential" teratogens would be most useful to obstetricians. Despite the fact that the authors' data failed to demonstrate a positive correlation between "teratogens" and major anomalies, they still have admonished physicians to decrease the exposure of pregnant women to drugs. Since I assume that all of the drugs prescribed in the authors' study
Meister der Heilkunde.
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Myopathy and rhabdomyolysis with lovastatin taken with gemfibrozil
Authors: Mark R. Goldstein
Journal: JAMA (1990)

<h3>To the Editor. —</h3> The article by Pierce et al<sup>1</sup>on myopathy and rhabdomyolysis associated with the combination of lovastatin and gemfibrozil has several important messages. Most important, it provides firm evidence that the concomitant use of lovastatin and gemfibrozil should be avoided because of the apparent synergism of this combination in causing myopathy and rhabdomyolysis. This report is timely since other investigators have recently published data that support the efficacy of this combination in treating mixed hyperlipidemia.<sup>2,3</sup> Of the 12 cases reported, eight were in women 65 years of age and older. Although disturbing, this is not surprising, since prescribing practices in 1988 revealed that cholesterol-lowering drugs were given predominantly to women and the elderly.<sup>4</sup>There have been no primary or secondary prevention trials of coronary heart disease using cholesterol-lowering drugs in women or the elderly to suggest their long-term safety and/or efficacy in decreasing end
Health-related quality-of-life (HRQoL) results from the FAST study, a phase 2 trial of epirubicin, oxaliplatin and capecitabine with or without IMAB362 in patients with advanced CLDN18.2+ gastric (GA) and gastroesophageal junction (GEJ) adenocarcinoma.
Authors: Robert Morlock, James Turnbul, Steven Blahut, Michelle R Krukas-Hampel, Emily Hawryluk, Özlem Tureci
Journal: Journal of Clinical Oncology (2018)

e16005 Background: In the FAST study, IMAB362 plus EOX was compared with EOX alone in patients with advanced/metastatic GA, gastroesophageal (GE), and GEJ adenocarcinoma. The FAST study demonstrated clinically relevant benefits in PFS and OS with a manageable safety profile in patients treated with IMAB362; here we present the HRQoL results from the FAST study. Methods: CLDN18.2-positive patients (intermediate/strong membrane staining in ≥40% of cells) with advanced/metastatic GA/GE/GEJ adenocarcinoma were randomized 1:1 to first-line EOX for a maximum of 8 cycles with or without 600 mg/m2 Q3W IMAB362, which after 8 cycles could be continued as monotherapy until disease progression (DP). The EORTC QLQC30 and a gastric cancer specific measure EORTC STO22 were collected at baseline (BL), Cycle 5, end of EOX therapy (EOT) and post-EOT every 12 weeks until DP. Change from BL in EORTC scores over 8 cycles of EOX treatment were analyzed using mixed model repeated measures. Time to deterioration in HRQoL was defined as time from randomization to first minimally clinically important difference (MCID) decline in each HRQoL domain. Results: HRQoL analysis included 74 EOX and 68 IMAB362 + EOX per protocol patients. There were no significant differences in mean changes from BL in EORTC QLQC30 Global Health Status/QoL Score and STO22 Total Score across the 8 cycles of treatment with EOX. The QLQC30 Nausea and Vomiting domain showed a statistical difference (p = 0.0108) in favor of EOX-only. The median time to first HRQoL MCID deterioration for the QLQC30 Global Health Status was 8.6 mo for EOX + IMAB362 and 6.0 mo for EOX alone (p = 0.008). For patients who remained on IMAB362 post EOT, HRQoL improved from BL. Interviews from nine GA/GEJ patients, outside of the FAST study, have confirmed HRQoL PRO measures used in the FAST study captured all the relevant HRQoL constructs. Conclusions: HRQoL was maintained for a longer duration in pts with advanced/metastatic GA/GE/GEJ adenocarcinoma who received EOX + IMAB362 therapy vs EOX alone. HRQoL post EOT was improved for EOX + IMAB362 therapy vs EOX alone. Clinical trial information: NCT01630083.
Croonian Lectures on Mind, Brain, and Spinal Cord, in Certain Morbid Conditions
Authors: C. B. Radcliffe
Journal: BMJ (1873)

THE subjects to which I would wish to direct attention in the present lecture are two in number.The first is a disorder which often occurs in practice, but which as yet, so far as I know, has escaped distinct re- cognition-a disorder which I would venture to call cerebral exhaustion.The second is a disorder closely akin to this, for which spinal exhaustion would seem to be a fitting name-a disorder often disguised under the mask of hysteria so called.In what I have to say there will be little about spinal exhaustion, for the hour allotted to me will be very nearly gone when I have said what I want to say upon the subject with which I choose to begin-namely, cerebral exhaustion; but this matters little in reality, for much of what is left unsaid would be little more than a repetition of what will be said.CONCERNING CEREBRAL EXHAUSTION.The symptoms of cerebral exhaustion are numerous and various; but, as I hope to show before I have-done, neither vague nor incon- stant.In considering them it matters little what plan is pursued, provided they are all included in it.It is, indeed, enough to take them seriatim, with little or no regard to any method of classification; and this is really what I propose to do.Or, if I do any more than this, it is merely to put them in certain groups, four in number, in which, without any sufficient reason, perhaps, they have come to arrange them- selves practically in my mind.Failure of memory, and of mental energy generally-sleepiness or the reverse-depression of spirits-and unusual irritability of the temper -are the symptoms, in all probability, which first arrest the attention, and which I would venture to place in the first of the four groups I have mentioned.The symptom first named-failure of mental energy, ofmemory most particularly-must be looked upon as the symptom of symptoms.Where the patient has no occasion to exercise his mind, this symptom may not force itself upon the attention; but not so in the contrary case.Here, without any questioning on the subject, the complaint made is almost sure to be that the " headwork", which was once easy, has become all but impossible, and that the little work done is not well done.It is no longer possible to fix the thoughts to the task in hand; the thoughts themselves have lost all vividness, and working in a hurry, workingagainst time, has become a thing scarcely to be thought qf, any pressure in this direction producing a state of helpless distress analogous to nightmare, instead of being, as it ought to be, and as it once was, a stimulus to exertion.
First Fire
Authors: E. M. McMahon
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Injuries associated with hang gliding
Authors: W. B. Krissof
Journal: JAMA (1975)

TEN THOUSAND people currently engage in hang gliding or sky-sailing as it is sometimes termed.<sup>1</sup>The main centers for this new sport are the cliffs of Southern California near the sea and the mountains of Colorado. By nature, soaring on a kite launched by running downhill and remaining aloft at the pleasure of the wind is a high-risk operation. This, as far as we know, is the first definition of the injuries that occur in this sport and of reasonable precautions to minimize such injuries. <h3>Fatal Accidents</h3><h3>Case 1.—</h3> On Nov 24, 1973, an instructor and designer for Chandelle Sky Sail of Colorado sustained fatal injuries when his "modern standard sail" went into a stall configuration and then a steep dive while he was gliding off the north aspect of Green Mountain immediately west of Denver. He had apparently understood that this craft had poor dive-recovery characteristics, and had